For these reasons, in this work we evaluated the tissue reactivity of ior egf/r3 Mab, the murine counterpart of nimotuzumab [8], in lung carcinomas as well as, the ability of this Mab to bind the extracellular domain of EGFR inhibiting cell proliferation and inducing apoptosis in a NSCLC cell line. The gene discussed is EGFR; the disease is lung carcinoma.